The Phoenix Partnership (TPP) and SystmOne: Valuation Assessment and Strategic Transaction Analysis
- Nelson Advisors
- 3 minutes ago
- 11 min read
Executive Summary
The Phoenix Partnership (Leeds) Ltd (TPP) represents one of the most profitable and entrenched software platforms within the United Kingdom's digital health infrastructure. Operating its proprietary electronic health record (EHR) platform, SystmOne, TPP maintains an entrenched duopoly alongside EMIS Health, together administering the clinical data and consultation workflows of more than 90% of general practices across England. In the financial year ending 31 March 2025, TPP demonstrated sustained commercial expansion, generating £97.1 million in turnover, a 12.9% increase year on year, alongside pre-tax profits of £47.4 Million and supporting an equity dividend distribution of £50.0 Million to its holding company.
Based on European and cross-border healthcare information technology (HCIT) transaction multiples, most notably the £1.24 billion acquisition of EMIS Group by Optum and the €1.22 billion privatisation of Nexus AG, TPP is evaluated at an estimated Enterprise Value (EV) range of £800 Million to £1.05 Billion, with a baseline central valuation of £925 Million. This valuation implies an EV/EBITDA multiple range of 16.0x to 20.0x and an EV/Revenue multiple of 8.2x to 10.8x on FY2025 financial results.
Despite operating margins in excess of 50%, an absence of structural bank debt, and minimal customer churn, a liquidity or sale process faces complex execution dynamics. Regulatory barriers enforced by the Competition and Markets Authority (CMA) effectively exclude direct domestic competitors, while reputational exposure surrounding founder Frank Hester necessitates a clear governance transition.
Consequently, institutional financial sponsors and international software consolidators represent the most viable acquirer universe.
Business Model and Strategic Positioning: The SystmOne Ecosystem
Founded in 1997 by software architect Frank Hester, TPP established its market position through a single, centrally hosted architectural model. In contrast to legacy peers that expanded by deploying distributed, site-level client server installations, SystmOne was engineered around a unified "one patient, one record" framework. Under this topology, all clinical encounters, pathology results, electronic prescriptions and demographic updates are committed to a centralised relational database storing longitudinal health records for more than 61 million registered UK individuals.
The primary care IT landscape within the National Health Service (NHS) exhibits extreme structural concentration. Successive procurement iterations, managed centrally under the GP Systems of Choice (GPSoC) and GP IT Futures frameworks, have systematically narrowed the field of accredited suppliers to an effective duopoly.
Primary Care Clinical System | Primary Operating Entity / Parent | English GP Practice Market Share | Core Architectural Footprint | Key Strategic Capabilities & Contract Scope |
SystmOne | The Phoenix Partnership (Leeds) Ltd | ~35% – 42% | Centrally hosted single database; native shared record model | High penetration across primary, community, mental health, and prison health sectors. |
EMIS Web | Optum UK (UnitedHealth Group) | ~55% – 57% | Hybrid cloud/hosted infrastructure; extensive third-party integration layer | Dominant primary care footprint; native integration with Optum population health and analytics tools. |
Vision | OneAdvanced (acquired from Cegedim in 2025) | ~5% – 9% | Modular cloud transition via Vision Anywhere | Established legacy customer base with specialized clinical workflow installations. |
Medicus Health | Medicus Health (Independent) | <0.5% | Cloud-native microservices architecture | Newly accredited market entrant attempting to dislodge incumbent vendor lock-in. |
The Herfindahl–Hirschman Index (HHI) for general practice EHR systems in England exceeds 5,100, signifying an exceptionally concentrated market structure. Annual customer churn has historically trended at approximately 1%, reflecting immense operational and technical switching costs. Displacing SystmOne requires a GP practice or Integrated Care Board (ICB) to execute comprehensive data extraction, remap complex SNOMED CT coding histories, and retrain entire clinical workforces.
Beyond its primary care foundation of more than 2,600 GP surgeries, TPP has successfully diversified horizontally across adjacent NHS settings. SystmOne is currently deployed across roughly one-third of England’s acute mental health trusts and holds widespread contracts across community health trusts, palliative care hospices and the vast majority of HM Prison Service health facilities.
To defend its perimeter against third party point solutions, TPP developed Brigid, a dedicated mobile clinician application for ward rounds and home visits and Airmid, an integrated patient engagement platform handling appointment management, messaging and clinical access. Furthermore, TPP has capitalised on national architecture projects, securing contracts such as the Wayfinder integration to link SystmOne directly with the centralised NHS App.
Financial Profile and Historical Cash Generation
Financial filings lodged with Companies House reveal that TPP is one of the most profitable mid-market software vendors in the UK enterprise software landscape. The company benefits from a single consolidated codebase, highly automated deployment pathways and negligible direct sales and marketing expenditures due to centralised NHS framework procurement.
Historical Financial Overview (FY2021 – FY2025)
The primary trading performance is reported through The Phoenix Partnership (Leeds) Ltd (Company No. 04077829), which is wholly owned by the holding entity TPP Finance Limited.
Financial Metric (£m) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
Turnover (Revenue) | £71.0m | £75.0m | £80.0m | £86.0m | £97.1m |
YoY Revenue Growth (%) | — | +5.6% | +6.7% | +7.5% | +12.9% |
Profit Before Tax (PBT) | £43.0m | £47.0m | £40.0m | £17.4m | £47.4m |
PBT Margin (%) | 60.5% | 62.7% | 50.0% | 20.2% | 48.8% |
Normalized EBITDA (Est.) | £45.0m | £49.0m | £42.0m | £29.0m | £51.5m |
Normalized EBITDA Margin (%) | 63.4% | 65.3% | 52.5% | 33.7% | 53.0% |
Annual Dividend Paid | £5.0m | £10.0m | £10.0m | £7.0m | £50.0m |
Source: Companies House
The business displays remarkable cash generation characteristics, supported by long term government framework arrangements and multi year trust- evel EPR contract extensions. Public sector spending records confirm that TPP has secured over £590 million in public sector receipts since 2016, with primary funding flows originating from the Department of Health and Social Care (DHSC) and NHS England.
Operating profit margins experienced a temporary contraction in FY2024, when PBT decreased to £17.4 million. This decline reflected a confluence of non capitalised software investments, heightened operational expenditures and non operational cash outflows, including £10.2 million in political donations.
In FY2025, operating leverage reasserted itself: PBT rebounded to £47.4 million on revenue of £97.1 million, enabling the declaration and extraction of a £50.0 million cash dividend. With capital expenditure requirements limited primarily to server infrastructure and office maintenance, free cash flow conversion routinely exceeds 90% of EBITDA, creating an exceptionally stable capital profile.
Standalone Valuation and Transaction Multiples
Establishing a transaction valuation for TPP requires balancing its peer-leading cash generation and defensible market position against the structural governance discounts stemming from founder concentration, historic political exposure and a single payer customer profile.
Comparable Precedent M&A Transactions
M&A activity in European and Anglo-American clinical software demonstrates that mission critical healthcare record systems command premium valuation multiples due to high customer retention, statutory integration barriers and clear visibility into recurring software revenues.
Target Company | Acquirer / Sponsor | Completion Date | Enterprise Value (EV) | EV / LTM Sales | EV / LTM EBITDA | Structural Parallels & Relevance |
EMIS Group plc | Optum (UnitedHealth Group) | Oct 2023 | £1.24 billion | 6.8x – 7.2x | 21.0x – 23.5x | Direct domestic duopoly peer in UK primary care; public listing premium. |
Nexus AG | TA Associates | Jan 2025 | €1.22 billion | 4.8x – 5.2x | 19.3x | European hospital information systems provider taken private. |
CompuGroup Medical | CVC Capital Partners (Bid) | 2024 / 2025 | €1.25 billion (EqV) | 3.5x – 4.0x | 14.5x – 16.5x | Pan-European ambulatory and hospital EHR market consolidator. |
Inovalon | Nordic Capital consortium | Nov 2021 | $7.31 billion | 10.2x | 32.9x | Mission-critical cloud analytics and healthcare clinical software platform. |
Cerner Corporation | Oracle Corporation | Jun 2022 | $29.4 billion | 5.2x | 19.6x | Global Tier-1 acute care and hospital EHR enterprise consolidation. |
Valuation parameters across the European HealthTech sector have bifurcated based on underlying profitability and mission criticality. Assets complying with the "Rule of 40", where the sum of year on year revenue growth and EBITDA margin exceeds 40%, command EV/EBITDA multiples between 16.0x and 22.0x. TPP significantly outperforms this operating benchmark: with a 12.9% revenue growth rate and a 53.0% normalised EBITDA margin in FY2025, its Rule of 40 score stands at 65.9%.
Valuation Matrix and Scenario Analysis
Applying prevailing market transaction parameters to TPP’s baseline FY2025 financial figures (£97.1 million turnover and £51.5 million estimated normalised EBITDA) yields three operational valuation cases.
Valuation Scenario | Implied EV / EBITDA | Implied EV / Revenue | Enterprise Value Range (£m) | Core Scenario Assumptions & Valuation Drivers |
Downside / Bear Case | 14.0x | 7.4x | £720m – £750m | Heightened political scrutiny under a Labour administration; customer attrition across community trusts; aggressive antitrust behavioral restrictions. |
Base Case (PE Buyout) | 17.5x | 9.3x | £900m – £950m | Orderly transition of executive leadership; institutionalization of software governance; preservation of core GP IT framework market share; stable cash flow conversion. |
Upside / Strategic Bull Case | 20.5x | 10.9x | £1,050m – £1,100m | Competitive auction involving foreign strategic buyers; successful commercial monetization of data assets; expansion across secondary care and international health systems. |
Founder Frank Hester historically asserted that TPP commanded a standalone valuation of £1.0 billion. Institutional corporate finance modelling substantiates that, on an unencumbered corporate basis, the intrinsic value of TPP's cash generation ranges firmly between £800 million and £1.05 billion, aligning with the £1.24 billion benchmark established by the sale of EMIS Group.
Strategic Acquirer Universe
Identifying potential strategic acquirers requires assessing both balance sheet capacity and the structural antitrust barriers inherent in the UK clinical software market.
Trade buyers operating global acute care EHR platforms represent natural suitors seeking to establish continuous, longitudinal patient records spanning acute, secondary and primary care settings. Oracle Health (Cerner) maintains a deep operational footprint across NHS acute hospital trusts but lacks a native UK primary care interface, leaving it reliant on external messaging brokers. Acquiring SystmOne would instantly grant Oracle ownership of over 35% of England’s general practice network, establishing an integrated acute-to-primary care clinical record. However, Oracle’s corporate integration efforts remain largely focused on migrating legacy Cerner environments to Oracle Cloud Infrastructure (OCI), which may temper immediate multi-billion-dollar appetite for regional assets.
Pan-European consolidators also exhibit structural alignment with TPP’s clinical scope. Dedalus Group, backed by private equity firm Ardian, has executed aggressive European consolidation across diagnostic software and hospital information systems, and acquiring SystmOne would instantly establish Dedalus as an essential pillar of UK health infrastructure. Similarly, Germany-based CompuGroup Medical (CGM) specialises in ambulatory clinical software across continental Europe. A transaction with TPP would provide CGM with substantial geographic diversification into the UK public sector, although CGM’s own leveraged balance sheet and recent take-private proposals may restrict its capacity to absorb an asset approaching £1 billion.
Domestic mid-market healthcare consolidators present alternative strategic combinations, though each carries regulatory friction. OneAdvanced, backed by Vista Equity Partners and BC Partners, acquired Vision in August 2025, the third largest primary care system in England. Uniting SystmOne with Vision would consolidate approximately 45% of the market under OneAdvanced, creating a direct counterweight to Optum/EMIS. Similarly, System C Healthcare, owned by CVC Capital Partners, has established market scale across acute, social care and community trusts via acquisitions such as Clevermed and Oxford Computer Consultants. Integrating SystmOne would connect System C’s social care modules directly to general practice records.
Financial Sponsor Universe and Private Equity Buyout Dynamics
Given the antitrust hurdles confronting domestic trade acquirers, private equity sponsors represent the cleanest and most probable execution pathway for a change of control transaction. TPP’s economic profile, characterised by predictable multi year cash flows, operating margins exceeding 50%, minimal bad debt, and high customer stickiness, matches the investment mandates of large-cap buyout funds.
Hg Capital stands out as a leading financial sponsor for TPP, given its focus on European vertical software and mission-critical public sector applications. Hg’s investment thesis would centre on institutionalising company governance, accelerating software as a service cloud migration, and professionalising customer engagement across Integrated Care Boards (ICBs). By decoupling corporate strategy from founder dependence and implementing recurring add on software modules, such as AI triage and advanced workforce management, Hg could expand customer lifetime value while maintaining a stable underlying cash yield.
TA Associates possesses direct, current sector domain experience following its successful €1.22 billion public-to-private tender offer for German EHR provider Nexus AG in January 2025. TA Associates could pursue a cross-border integration strategy, evaluating operational efficiencies and technological integration between Nexus AG’s modular clinical software and TPP’s primary care database, thereby creating a pan-European EHR platform.
Nordic Capital similarly represents a high-conviction candidate, having demonstrated an appetite for scaled healthcare software transactions through its $7.3 billion acquisition of Inovalon. Nordic Capital’s operational playbook typically targets regulatory-driven healthcare environments, where it accelerates organic growth by funding standardised API interoperability and expanding cross-border sales across Scandinavia and continental Europe.
Bridgepoint provides extensive familiarity with the UK National Health Service, having previously built out System C Healthcare and held investments in independent care delivery providers such as Practice Plus Group. Bridgepoint’s operational approach would focus on repairing strategic relationships with NHS procurement bodies, ensuring contract continuity across primary and community care frameworks, and optimising central commercial pricing.
Other global mega-funds, including EQT Partners, Thoma Bravo, and KKR, maintain dedicated healthcare and software strategies capable of writing the £400 million to £500 million equity checks required for a leveraged buyout of this scale. A private equity buyout would utilise conservative structural leverage (approximately 5.0x to 6.0x EBITDA), supported by TPP’s resilient recurring cash generation, without compromising day to day software development operations.
Regulatory, Antitrust and Operational Execution Headwinds
Any change-of-control transaction involving TPP must resolve three material structural risks that directly impact buyer risk premiums and transaction execution.
Antitrust Scrutiny and CMA Oversight
The UK Competition and Markets Authority maintains aggressive regulatory surveillance over digital health acquisitions. The 2023 Phase 2 inquiry into Optum’s acquisition of EMIS established a clear legal precedent regarding vertical data access and horizontal concentration in primary care. While the CMA eventually granted unconditional clearance to Optum after verifying that NHS oversight prevented vertical foreclosure, any transaction involving an acquirer with overlapping clinical software, medicines optimization platforms, or population health analytics would face immediate Phase 1 scrutiny and a probable Phase 2 reference. A buyout by an unaligned financial sponsor represents the most straightforward regulatory clearance route, circumventing competitive overlap concerns entirely.
Governance Transition and Founder Disentanglement
TPP’s operational model and corporate culture were historically defined by Frank Hester, who served as sole director and controlling shareholder. However, Hester’s public controversies in March 2024, surrounding reported derogatory remarks regarding MP Diane Abbott, created substantial operational exposure, prompting public sector unions, political figures and several NHS trusts to scrutinise commercial relationships.
Companies House filings demonstrate that in September 2025, Hester resigned his directorship of The Phoenix Partnership (Leeds) Ltd, being replaced on the board by Maria Tomasso, while long-serving executive Charlotte Knowles formally assumed the position of Chief Executive Officer.
While Hester retains beneficial ownership via his controlling stake in TPP Finance Limited, an institutional sale or private equity recapitalisation would require a complete operational and equity exit. Institutional capital partners will mandate an unencumbered corporate separation to insulate NHS contracts from ongoing political debate.
Technical Architecture and Interoperability Mandates
Historically, SystmOne operated as a closed ecosystem, delivering superior cross organisation functionality between its own modules while presenting technical barriers to third-party software integration. NHS England’s strategic procurement requirements under the Digital Care and GP IT Futures frameworks increasingly mandate open architectures, strict compliance with HL7 FHIR (Fast Healthcare Interoperability Resources) API's and native cloud infrastructure. While TPP has made strategic progress, securing NHS Booking Standard API compliance and establishing direct connections to the central NHS App via Wayfinder, incoming investors will need to allocate capital expenditure toward modernising the core platform into a cloud-native, microservices driven framework to mitigate the risk of long-term architectural obsolescence.
Transaction Conclusions and Strategic Outlook
The Phoenix Partnership represents a unique combination of extreme profitability, non-discretionary public sector revenue and structural market entrenchment. Generating £97.1 million in revenue and operating profits approaching £50 million, the asset is supported by strong underlying economics and commands an institutional valuation range between £800 million and £1.05 billion.
Because antitrust barriers effectively prevent a sale to existing UK primary care providers, the most credible exit route is a sponsor-backed leveraged buyout led by software-focused private equity firms such as Hg Capital, TA Associates, or Nordic Capital.
Realising the upper end of the valuation spectrum (£1.0+ billion) will depend on an incoming owner successfully completing the governance transition away from founder ownership, modernising SystmOne's legacy technical architecture to satisfy NHS open-API mandates, and capitalising on the platform's longitudinal data assets across secondary and international care markets.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk
Comments